Our last day of testing for the year will be 22 December. The lab will start up again on 2 January 2024.
You can still place new orders and send us samples while we are on break, ready for when we reopen.
Myxomatous mitral valve disease (MMVD)
This test is based on recent research that identified genetic variants associated with increased risk of early-onset myxomatous mitral valve disease (MMVD). It determines a dog's genotype for the genetic variant referred to as NEBL3 in the scientific paper referenced below.
Dogs with a G G or A G test result are less likely to be diagnosed with MMVD early in life compared to dogs with an A A result. Very few Cavalier King Charles Spaniels have the G variant, and identifying these dogs could help breeders who want to produce healthier pups.The test was developed based on data from Cavalier King Charles Spaniel and Dachshund dogs and should not be used on other dog breeds. The test is likely to be updated if further research suggests other genetic variants are more useful predictors of MMVD severity or time of onset.
Gene or region and technical reference
Gene: NEBL (marker). Reference: Axelsson et al. (2021)
G. Test developed using artificial DNA, animal controls.
A. Test developed using artificial DNA, animal carriers.
Panels: groups of tests that are often ordered together
This test is not in any panels.